{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:18:35Z","timestamp":1747196315517,"version":"3.40.5"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Transurethral resection of prostate (TURP) and laser prostate surgery are common surgeries for benign prostate hyperplasia (BPH). We conducted an investigation using hospital database to evaluate the clinical factors associated with post-operative usage of alpha-blockers and antispasmodics.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study was conducted using retrospective clinical data from the hospital database, which contained newly diagnosed BPH patients between January 2007 and December 2012 who subsequently received prostate surgery. The study end-point was the use of alpha-blockers or antispasmodics for at least 3 months duration after 1 month of surgery. The exclusion criteria was prostate cancer diagnosed before or after the surgery, recent transurethral surgeries, history of open prostatectomy, and history of spinal cord injury. Clinical parameters, including age, body mass index, preoperative prostate specific antigen value, comorbidities, preoperative usage of alpha-blockers, anstispasmodics and 5-alpha reductase inhibitors, surgical methods, resected prostate volume ratios, and preoperative urine flow test results, were evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 250 patients receiving prostate surgery in the database and confirmed pathologically benign were included. There was significant association between chronic kidney disease (CKD) and the usage of alpha-blockers after prostate surgery (OR = 1.93, 95% CI 1.04\u20133.56, p = 0.036). Postoperative antispasmodics usage was significantly associated with preoperative usage of antispasmodics (OR = 2.33, 95% CI 1.02\u20135.36, p = 0.046) and resected prostate volume ratio (OR = 0.12, 95% CI 0.02\u20130.63, p = 0.013).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>BPH patients with underlying CKD were more likely to require alpha-blockers after surgery. In the meantime, BPH patients who required antispasmodics before surgery and who received lower prostate volume resection ratio were more liable to antispasmodics after prostate surgery.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0282745","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T18:47:45Z","timestamp":1678387665000},"page":"e0282745","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic kidney disease, preoperative use of antispasmodics and lower resected prostate volume ratios are risk factors for postoperative use of adrenergic Alpha-blockers and antispasmodics"],"prefix":"10.1371","volume":"18","author":[{"given":"Chen-Hsun","family":"Hsueh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Yuan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Chun","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4626-9369","authenticated-orcid":true,"given":"Jian-Ri","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"3","key":"pone.0282745.ref001","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"SJ Berry","year":"1984","journal-title":"J Urol"},{"issue":"5 Suppl 1","key":"pone.0282745.ref002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(00)00742-1","article-title":"LUTS, ED, QOL: alphabet soup or real concerns to aging men?","volume":"56","author":"MP O\u2019Leary","year":"2000","journal-title":"Urology"},{"issue":"5","key":"pone.0282745.ref003","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/nau.10057","article-title":"Detrusor instability with equivocal obstruction: A predictor of unfavorable symptomatic outcomes after transurethral prostatectomy.","volume":"21","author":"R Machino","year":"2002","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"pone.0282745.ref004","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.juro.2008.03.058","article-title":"Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients","volume":"180","author":"O Reich","year":"2008","journal-title":"J Urol"},{"issue":"3","key":"pone.0282745.ref005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)32614-9","article-title":"Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment","volume":"152","author":"EK Seaman","year":"1994","journal-title":"J Urol"},{"issue":"3","key":"pone.0282745.ref006","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.urology.2014.04.027","article-title":"Factors associated with continuing medical therapy after transurethral resection of prostate","volume":"84","author":"HH Han","year":"2014","journal-title":"Urology"},{"issue":"5","key":"pone.0282745.ref007","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0022-5347(17)37546-8","article-title":"The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia","volume":"147","author":"E Shapiro","year":"1992","journal-title":"J Urol"},{"issue":"4","key":"pone.0282745.ref008","first-page":"181","article-title":"Alpha blockers for the treatment of benign prostatic hyperplasia","volume":"9","author":"H. Lepor","year":"2007","journal-title":"Rev Urol"},{"issue":"9","key":"pone.0282745.ref009","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1464-410X.2010.09359.x","article-title":"Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an \u03b1-blocker: effect of baseline prostate-specific antigen concentration.","volume":"106","author":"CR Chapple","year":"2010","journal-title":"BJU Int"},{"issue":"6","key":"pone.0282745.ref010","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1523-1755.2005.00344.x","article-title":"The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men","volume":"67","author":"AD Rule","year":"2005","journal-title":"Kidney Int"},{"issue":"10","key":"pone.0282745.ref011","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1464-410X.2009.08975.x","article-title":"Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.","volume":"105","author":"SK Hong","year":"2010","journal-title":"BJU Int"},{"issue":"2","key":"pone.0282745.ref012","doi-asserted-by":"crossref","first-page":"O202","DOI":"10.1111\/luts.12240","article-title":"Changes in sensory proteins in the bladder urothelium of patients with chronic kidney disease and end-stage renal disease","volume":"11","author":"SF Chen","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"issue":"2","key":"pone.0282745.ref013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/j.ajkd.2020.07.018","article-title":"Kidney, Cardiac, and Safety Outcomes Associated With \u03b1-Blockers in Patients With CKD: A Population-Based Cohort Study","volume":"77","author":"GL Hundemer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"pone.0282745.ref014","first-page":"71","article-title":"Review of the epidemiology of overactive bladder.","volume":"8","author":"RS Eapen","year":"2016","journal-title":"Res Rep Urol"},{"issue":"6","key":"pone.0282745.ref015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.","volume":"94","author":"JY Lee","year":"2004","journal-title":"BJU Int."},{"issue":"12","key":"pone.0282745.ref016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11934-020-01003-z","article-title":"Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?","volume":"21","author":"C Fogaing","year":"2020","journal-title":"Current urology reports"},{"issue":"3","key":"pone.0282745.ref017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000447205","article-title":"Overactive Bladder Syndrome: Evaluation and Management.","volume":"11","author":"E Leron","year":"2018","journal-title":"Curr Urol"},{"issue":"6","key":"pone.0282745.ref018","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.urology.2015.07.019","article-title":"Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia","volume":"86","author":"SA Strope","year":"2015","journal-title":"Urology"},{"issue":"10","key":"pone.0282745.ref019","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4111\/kju.2010.51.10.700","article-title":"Analysis of the factors causing bladder irritation after transurethral resection of the prostate","volume":"51","author":"TI Kim","year":"2010","journal-title":"Korean J Urol"},{"key":"pone.0282745.ref020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2019.05.003","article-title":"The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy","volume":"130","author":"J Campbell","year":"2019","journal-title":"Urology"},{"issue":"6","key":"pone.0282745.ref021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5152\/tud.2020.20202","article-title":"Is Thulium laser enucleation of prostate an alternative to Holmium and TURP surgeries\u2014A systematic review?","volume":"46","author":"MM Wani","year":"2020","journal-title":"Turk J Urol"},{"issue":"1","key":"pone.0282745.ref022","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2015.07.054","article-title":"A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study.","volume":"69","author":"JA Thomas","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"pone.0282745.ref023","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/01.ju.0000136218.11998.9e","article-title":"Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients","volume":"172","author":"RM Kuntz","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"pone.0282745.ref024","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1464-410x.2000.00433.x","article-title":"The correlation between clinical outcome and residual prostatic weight ratio after transurethral resection of the prostate for benign prostatic hyperplasia","volume":"85","author":"SS Chen","year":"2000","journal-title":"BJU Int"},{"issue":"4","key":"pone.0282745.ref025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000052478","article-title":"Is there a relationship between the amount of tissue removed at transurethral resection of the prostate and clinical improvement in benign prostatic hyperplasia","volume":"39","author":"OW Hakenberg","year":"2001","journal-title":"Eur Urol"},{"issue":"4","key":"pone.0282745.ref026","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11934-008-0050-z","article-title":"Persistent detrusor overactivity after transurethral resection of the prostate","volume":"9","author":"F Housami","year":"2008","journal-title":"Curr Urol Rep"},{"issue":"1","key":"pone.0282745.ref027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(05)67450-2","article-title":"A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study","volume":"164","author":"JL Donovan","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"pone.0282745.ref028","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(05)63949-3","article-title":"The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction","volume":"169","author":"C de Nunzio","year":"2003","journal-title":"J Urol"},{"issue":"6","key":"pone.0282745.ref029","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.juro.2014.12.095","article-title":"Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate?","volume":"193","author":"AA Antunes","year":"2015","journal-title":"J Urol"},{"issue":"11","key":"pone.0282745.ref030","doi-asserted-by":"crossref","first-page":"e021889","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.","volume":"8","author":"G Yeowell","year":"2018","journal-title":"BMJ Open"},{"issue":"5","key":"pone.0282745.ref031","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.urology.2011.05.017","article-title":"Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes","volume":"78","author":"RT Liu","year":"2011","journal-title":"Urology"},{"issue":"9","key":"pone.0282745.ref032","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1442-2042.2010.02579.x","article-title":"Bladder function of end-stage renal disease patients","volume":"17","author":"K Tsunoyama","year":"2010","journal-title":"Int J Urol"},{"issue":"5","key":"pone.0282745.ref033","doi-asserted-by":"crossref","first-page":"e0156133","DOI":"10.1371\/journal.pone.0156133","article-title":"Comparison of Photoselective Vaporization versus Holmium Laser Enucleation for Treatment of Benign Prostate Hyperplasia in a Small Prostate Volume","volume":"11","author":"KS Kim","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0282745.ref034","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.juro.2012.02.2576","article-title":"Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial","volume":"188","author":"H Elmansy","year":"2012","journal-title":"J Urol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0282745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T18:48:10Z","timestamp":1678387690000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0282745"}},"subtitle":[],"editor":[{"given":"Mohammad","family":"Saleem","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0282745","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}